دورية أكاديمية
أعرض في EDS

Serum Type XIX Collagen is Significantly Elevated in Non-Small Cell Lung Cancer: A Preliminary Study on Biomarker Potential.

التفاصيل البيبلوغرافية
العنوان: Serum Type XIX Collagen is Significantly Elevated in Non-Small Cell Lung Cancer: A Preliminary Study on Biomarker Potential.
المؤلفون: Thorlacius-Ussing J; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.; Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Manon-Jensen T; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark., Sun S; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark., Leeming DJ; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark., Sand JM; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark., Karsdal M; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark., Willumsen N; Biomarkers and Research, Nordic Bioscience A/S, 2730 Herlev, Denmark.
المصدر: Cancers [Cancers (Basel)] 2020 Jun 09; Vol. 12 (6). Date of Electronic Publication: 2020 Jun 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Type XIX collagen is a poorly characterized collagen associated with the basement membrane. It is abnormally regulated during breast cancer progression and the NC1 (XIX) domain has anti-tumorigenic signaling properties. However, little is known about the biomarker potential of collagen XIX in cancer. In this study, we describe a competitive ELISA, named PRO-C19, targeting the C-terminus of collagen XIX using a monoclonal antibody. PRO-C19 was measured in serum of patients with a range of cancer types and was elevated in non-small cell lung cancer (NSCLC) ( p < 0.0001), small cell lung cancer ( p = 0.0081), breast ( p = 0.0005) and ovarian cancer ( p < 0.0001) compared to healthy controls. In a separate NSCLC cohort, PRO-C19 was elevated compared to controls when evaluating adenocarcinoma (AD) ( p = 0.0003) and squamous cell carcinoma (SCC) ( p < 0.0001) patients but was not elevated in chronic obstructive pulmonary disease patients. SCC also had higher PRO-C19 levels than AD ( p = 0.0457). PRO-C19 could discriminate between NSCLC and healthy controls (AUROC:0.749 and 0.826 for AD and SCC, respectively) and maintained discriminatory performance in patients of tumor stages I+II (AUROC:0.733 and 0.818 for AD and SCC, respectively). Lastly, we confirmed the elevated type XIX collagen levels using gene expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) initiatives. In conclusion, type XIX collagen is released into circulation and is significantly elevated in the serum of cancer patients and PRO-C19 shows promise as a cancer biomarker.
References: Cancer Biol Ther. 2019;20(5):692-699. (PMID: 30626261)
Cancers (Basel). 2019 Aug 15;11(8):. (PMID: 31443252)
Int J Epidemiol. 2017 Aug 1;46(4):1104-1104i. (PMID: 27789666)
J Cell Biol. 2016 Mar 14;212(6):721-36. (PMID: 26975851)
J Biochem. 1995 Jan;117(1):137-46. (PMID: 7775380)
Neoplasia. 2017 Apr;19(4):271-278. (PMID: 28282545)
J Pathol. 2003 Mar;199(3):298-308. (PMID: 12579531)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Oncotarget. 2016 Jan 12;7(2):1516-28. (PMID: 26621838)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cancer Metastasis Rev. 2016 Dec;35(4):645-654. (PMID: 27878502)
Cancers (Basel). 2013 Jan 15;5(1):27-47. (PMID: 24216697)
J Biol Chem. 2003 Aug 22;278(34):32047-57. (PMID: 12788917)
BMC Pulm Med. 2017 Aug 9;17(1):110. (PMID: 28793886)
Nat Biotechnol. 2017 Apr 11;35(4):314-316. (PMID: 28398314)
Transl Oncol. 2018 Apr;11(2):528-534. (PMID: 29524830)
Int J Cancer. 2018 Dec 1;143(11):3027-3034. (PMID: 29923614)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
J Biol Chem. 1997 Jul 4;272(27):17104-11. (PMID: 9202028)
Transl Oncol. 2019 May;12(5):693-698. (PMID: 30856553)
PLoS One. 2012;7(3):e32632. (PMID: 22412900)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Cancer Med. 2014 Oct;3(5):1136-45. (PMID: 25044252)
J Biol Chem. 1994 Jul 15;269(28):18549-57. (PMID: 8034603)
Oncotarget. 2015 Feb 28;6(6):3656-68. (PMID: 25668817)
Am J Physiol Lung Cell Mol Physiol. 2000 Jan;278(1):L217-26. (PMID: 10645910)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a004978. (PMID: 21421911)
Transl Oncol. 2019 Feb;12(2):368-374. (PMID: 30504086)
Biochem Biophys Rep. 2018 Nov 30;17:38-43. (PMID: 30555938)
Cell Adh Migr. 2010 Jan-Mar;4(1):124-9. (PMID: 20139694)
BMC Cancer. 2013 Nov 21;13:554. (PMID: 24261855)
Amyotroph Lateral Scler. 2011 Jul;12(4):250-6. (PMID: 21375368)
Cancers (Basel). 2016 Aug 29;8(9):. (PMID: 27589803)
Aging Dis. 2019 Apr 1;10(2):278-292. (PMID: 31011479)
Mol Cancer Ther. 2007 Feb;6(2):506-14. (PMID: 17308049)
Int J Mol Sci. 2018 Sep 19;19(9):. (PMID: 30235830)
J Immunother Cancer. 2018 Dec 19;6(1):152. (PMID: 30567561)
Mayo Clin Proc. 2008 May;83(5):584-94. (PMID: 18452692)
Int J Cancer. 2020 May 15;146(10):2913-2922. (PMID: 31642523)
Sci Rep. 2019 Dec 24;9(1):19761. (PMID: 31875000)
J Cancer Res Clin Oncol. 2019 Feb;145(2):383-392. (PMID: 30467633)
Neurobiol Aging. 2015 Feb;36(2):1105-9. (PMID: 25475535)
Oncotarget. 2019 Nov 26;10(63):6829-6841. (PMID: 31827725)
Anal Biochem. 2013 Jun 15;437(2):111-7. (PMID: 23499763)
J Histochem Cytochem. 2001 Jun;49(6):711-26. (PMID: 11373318)
Am J Pathol. 1997 Dec;151(6):1729-40. (PMID: 9403723)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Genomics. 1992 Jul;13(3):884-6. (PMID: 1639419)
EMBO Rep. 2014 Dec;15(12):1243-53. (PMID: 25381661)
Cancer Biol Ther. 2018;19(10):904-912. (PMID: 30067436)
معلومات مُعتمدة: - Danish Research Foundation
فهرسة مساهمة: Keywords: AD; Collagen XIX; ECM; NSCLC; SCC; biomarker; cancer; serum
تواريخ الأحداث: Date Created: 20200613 Latest Revision: 20200928
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7352985
DOI: 10.3390/cancers12061510
PMID: 32527017
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers12061510